as 06-20-2025 4:00pm EST
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Founded: | 2016 | Country: | United States |
Employees: | N/A | City: | NEW YORK |
Market Cap: | 67.1M | IPO Year: | N/A |
Target Price: | $11.60 | AVG Volume (30 days): | 2.4M |
Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.95 | EPS Growth: | N/A |
52 Week Low/High: | $0.56 - $2.11 | Next Earning Date: | 08-07-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Tardio Jason | IMUX | President and COO | Jun 5 '25 | Buy | $0.79 | 12,512 | $9,884.48 | 12,512 | |
Vitt Daniel | IMUX | CEO and Director | Jun 4 '25 | Buy | $0.77 | 15,000 | $11,550.00 | 29,000 | |
Neermann Joerg | IMUX | Director | Jun 4 '25 | Buy | $0.77 | 100,000 | $76,700.00 | 170,000 | |
Whaley Glenn | IMUX | Chief Financial Officer | Jun 3 '25 | Buy | $0.71 | 45,000 | $32,076.00 | 95,510 | |
Rudick Richard Alan | IMUX | Director | Jun 3 '25 | Buy | $0.70 | 143,075 | $100,023.73 | 230,375 |
IMUX Breaking Stock News: Dive into IMUX Ticker-Specific Updates for Smart Investing
Argus Research
15 days ago
MT Newswires
16 days ago
PR Newswire
16 days ago
PR Newswire
18 days ago
PR Newswire
19 days ago
MT Newswires
23 days ago
PR Newswire
23 days ago
MT Newswires
24 days ago
The information presented on this page, "IMUX Immunic Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.